Differential expression of nicotinamide N-methyltransferase in primary and recurrent ameloblastomas and odontogenic keratocysts.
Adolescent
Adult
Aged
Aged, 80 and over
Ameloblastoma
/ metabolism
Female
Humans
Immunohistochemistry
Jaw Diseases
/ metabolism
Jaw Neoplasms
/ metabolism
Male
Middle Aged
Neoplasm Recurrence, Local
/ metabolism
Nicotinamide N-Methyltransferase
/ metabolism
Odontogenic Cysts
/ metabolism
Retrospective Studies
Young Adult
NNMT
ameloblastoma
immunohistochemistry
odontogenic keratocyst
odontogenic tumours
Journal
European journal of clinical investigation
ISSN: 1365-2362
Titre abrégé: Eur J Clin Invest
Pays: England
ID NLM: 0245331
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
14
08
2019
revised:
02
01
2020
accepted:
01
03
2020
pubmed:
5
3
2020
medline:
11
3
2021
entrez:
5
3
2020
Statut:
ppublish
Résumé
Odontogenic tumours are a group of rare heterogeneous diseases that range from hamartomatous tissue proliferations to benign and malignant neoplasms. Recurrences can occur after 10 years, so long-term clinical and radiological follow-up is required. The study of the molecular mechanisms involved in the development of these lesions is necessary to identify new prognostic markers. In this study, we evaluate the possible role of nicotinamide N-methyltransferase (NNMT) in ameloblastomas (AM) and odontogenic keratocysts (OKC). A total of 105 surgical specimens of primary and recurrent lesions were obtained from 55 patients (25 AM, 30 OKC). In particular, 50 AMs (25 primary, 25 recurrences) and 55 OKCs (30 primary, 25 recurrences) were retrieved. We carried out immunohistochemical analyses to evaluate the cytoplasmic expression of NNMT, measuring the percentage of positive cells and the value of NNMT expression intensity. NNMT expression was significantly higher in recurrent than primary AMs (P = .0430). This result was confirmed by staining intensity, showing more cases with moderate/intense staining in recurrent AMs (P = .0470). NNMT expression was significantly lower in recurrent than primary OKC (P = .0014). Staining intensity showed more cases with moderate/intense staining in primary OKCs (P = .0276). This report is the first to evaluate NNMT expression in odontogenic lesions and to demonstrate a differential expression in recurrent AMs and OKCs, suggesting that there is potential for use of NNMT as prognostic marker.
Sections du résumé
BACKGROUND
BACKGROUND
Odontogenic tumours are a group of rare heterogeneous diseases that range from hamartomatous tissue proliferations to benign and malignant neoplasms. Recurrences can occur after 10 years, so long-term clinical and radiological follow-up is required. The study of the molecular mechanisms involved in the development of these lesions is necessary to identify new prognostic markers. In this study, we evaluate the possible role of nicotinamide N-methyltransferase (NNMT) in ameloblastomas (AM) and odontogenic keratocysts (OKC).
MATERIALS AND METHODS
METHODS
A total of 105 surgical specimens of primary and recurrent lesions were obtained from 55 patients (25 AM, 30 OKC). In particular, 50 AMs (25 primary, 25 recurrences) and 55 OKCs (30 primary, 25 recurrences) were retrieved. We carried out immunohistochemical analyses to evaluate the cytoplasmic expression of NNMT, measuring the percentage of positive cells and the value of NNMT expression intensity.
RESULTS
RESULTS
NNMT expression was significantly higher in recurrent than primary AMs (P = .0430). This result was confirmed by staining intensity, showing more cases with moderate/intense staining in recurrent AMs (P = .0470). NNMT expression was significantly lower in recurrent than primary OKC (P = .0014). Staining intensity showed more cases with moderate/intense staining in primary OKCs (P = .0276).
CONCLUSIONS
CONCLUSIONS
This report is the first to evaluate NNMT expression in odontogenic lesions and to demonstrate a differential expression in recurrent AMs and OKCs, suggesting that there is potential for use of NNMT as prognostic marker.
Substances chimiques
NNMT protein, human
EC 2.1.1.1
Nicotinamide N-Methyltransferase
EC 2.1.1.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13220Informations de copyright
© 2020 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd.
Références
Rubini C, Mascitti M, Santarelli A, et al. Odontogenic tumors: a retrospective clinicopathological study from two Italian centers. Pathologica. 2017;109(1):35-46.
El-Naggar A, Chan J, Rubin Grandis J, Takata T, Slootweg P eds. WHO Classification of Head and Neck Tumours (4 edn). Lyon, France: International Agency for Research on Cancer; 2017. World Health Organization classification of tumours.
Lo Muzio L, Mascitti M, Santarelli A, et al. Cystic lesions of the jaws: a retrospective clinicopathologic study of 2030 cases. Oral Surg Oral Med Oral Pathol Oral Radiol. 2017;124(2):128-138.
Mascitti M, Togni L, Troiano G, et al. Odontogenic tumours: a 25-year epidemiological study in the Marche region of Italy. Eur Arch Otorhinolaryngol. 2020;277(2):527-538.
Buchner A, Merrell PW, Carpenter WM. Relative frequency of central odontogenic tumors: a study of 1,088 cases from Northern California and comparison to studies from other parts of the world. J Oral Maxillofac Surg. 2006;64(9):1343-1352.
Hayward JR. Recurrent ameloblastoma 30 years after surgical treatment. J Oral Surg. 1973;31(5):368-370.
Al-Moraissi EA, Dahan AA, Alwadeai MS, et al. What surgical treatment has the lowest recurrence rate following the management of keratocystic odontogenic tumor? A large systematic review and meta-analysis. J Craniomaxillofac Surg. 2017;45(1):131-144.
Barnes L, Eveson JW, Reichart P, Sidransky D eds. Pathology and Genetics of Head and Neck Tumours. Lyon, France: IARC Press; 2005. World Health Organization classification of tumours.
Aksoy S, Szumlanski CL, Weinshilboum RM. Human liver nicotinamide N-methyltransferase. cDNA cloning, expression, and biochemical characterization. J Biol Chem. 1994;269(20):14835-14840.
Pozzi V, Sartini D, Morganti S, et al. RNA-mediated gene silencing of nicotinamide N-methyltransferase is associated with decreased tumorigenicity in human oral carcinoma cells. PLoS One. 2013;8(8):e71272.
Peng Y, Sartini D, Pozzi V, Wilk D, Emanuelli M, Yee VC. Structural basis of substrate recognition in human nicotinamide N-methyltransferase. Biochemistry. 2011;50(36):7800-7808.
Sartini D, Seta R, Pozzi V, et al. Role of nicotinamide N-methyltransferase in non-small cell lung cancer: in vitro effect of shRNA-mediated gene silencing on tumourigenicity. Biol Chem. 2015;396(3):225-234.
Sartini D, Muzzonigro G, Milanese G, et al. Upregulation of tissue and urinary nicotinamide N-methyltransferase in bladder cancer: potential for the development of a urine-based diagnostic test. Cell Biochem Biophys. 2013;65(3):473-483.
Seta R, Mascitti M, Campagna R, et al. Overexpression of nicotinamide N-methyltransferase in HSC-2 OSCC cell line: effect on apoptosis and cell proliferation. Clin Oral Investig. 2019;23(2):829-838.
Mascitti M, Santarelli A, Sartini D, et al. Analysis of nicotinamide N-methyltransferase in oral malignant melanoma and potential prognostic significance. Melanoma Res. 2019;29(2):151-156.
D'Andrea FP, Safwat A, Kassem M, Gautier L, Overgaard J, Horsman MR. Cancer stem cell overexpression of nicotinamide N-methyltransferase enhances cellular radiation resistance. Radiother Oncol. 2011;99(3):373-378.
Emanuelli M, Santarelli A, Sartini D, et al. Nicotinamide N-Methyltransferase upregulation correlates with tumour differentiation in oral squamous cell carcinoma. Histol Histopathol. 2010;25(1):15-20.
Kim J, Hong SJ, Lim EK, et al. Expression of nicotinamide N-methyltransferase in hepatocellular carcinoma is associated with poor prognosis. J Exp Clin Cancer Res. 2009;28:20.
Speight PM, Takata T. New tumour entities in the 4th edition of the World Health Organization Classification of Head and Neck tumours: odontogenic and maxillofacial bone tumours. Virchows Arch. 2018;472(3):331-339.
Rahmanzadeh R, Huttmann G, Gerdes J, Scholzen T. Chromophore-assisted light inactivation of pKi-67 leads to inhibition of ribosomal RNA synthesis. Cell Prolif. 2007;40(3):422-430.
da Silva LP, Serpa MS, Santana T, do Nascimento GJ, de Souza Andrade ES, Sobral AP. Clinicopathological and cell proliferation evaluation of ameloblastomas and keratocystic odontogenic tumors: a 10 year retrospective study. Eur Arch Otorhinolaryngol. 2017;274(2):1089-1095.
Li TJ, Browne RM, Matthews JB. Epithelial cell proliferation in odontogenic keratocysts: a comparative immunocytochemical study of Ki67 in simple, recurrent and basal cell naevus syndrome (BCNS)-associated lesions. J Oral Pathol Med. 1995;24(5):221-226.
Jaafari-Ashkavandi Z, Mehranmehr F, Roosta E. MCM3 and Ki67 proliferation markers in odontogenic cysts and ameloblastoma. J Oral Biol Craniofac Res. 2019;9(1):47-50.
Sartini D, Muzzonigro G, Milanese G, Pierella F, Rossi V, Emanuelli M. Identification of nicotinamide N-methyltransferase as a novel tumor marker for renal clear cell carcinoma. J Urol. 2006;176(5):2248-2254.
Campagna R, Cecati M, Pozzi V, et al. Involvement of transforming growth factor beta 1 in the transcriptional regulation of nicotinamide N-methyltransferase in clear cell renal cell carcinoma. Cell Mol Biol. 2018;64(7):51-55.
Sartini D, Santarelli A, Rossi V, et al. Nicotinamide N-methyltransferase upregulation inversely correlates with lymph node metastasis in oral squamous cell carcinoma. Mol Med. 2007;13(7-8):415-421.
Sartini D, Pozzi V, Renzi E, et al. Analysis of tissue and salivary nicotinamide N-methyltransferase in oral squamous cell carcinoma: basis for the development of a noninvasive diagnostic test for early-stage disease. Biol Chem. 2012;393(6):505-511.
Sartini D, Morganti S, Guidi E, et al. Nicotinamide N-methyltransferase in non-small cell lung cancer: promising results for targeted anti-cancer therapy. Cell Biochem Biophys. 2013;67(3):865-873.
Pozzi V, Di Ruscio G, Sartini D, et al. Clinical performance and utility of a NNMT-based urine test for bladder cancer. Int J Biol Markers. 2018;33(1):94-101.
Ganzetti G, Sartini D, Campanati A, et al. Nicotinamide N-methyltransferase: potential involvement in cutaneous malignant melanoma. Melanoma Res. 2018;28(2):82-88.
Pozzi V, Mazzotta M, Lo Muzio L, et al. Inhibiting proliferation in KB cancer cells by RNA interference-mediated knockdown of nicotinamide N-methyltransferase expression. Int J Immunopathol Pharmacol. 2011;24(1):69-77.
Tang SW, Yang TC, Lin WC, et al. Nicotinamide N-methyltransferase induces cellular invasion through activating matrix metalloproteinase-2 expression in clear cell renal cell carcinoma cells. Carcinogenesis. 2011;32(2):138-145.
Zhang J, Wang Y, Li G, Yu H, Xie X. Down-regulation of nicotinamide N-methyltransferase induces apoptosis in human breast cancer cells via the mitochondria-mediated pathway. PLoS One. 2014;9(2):e89202.
Pozzi V, Sartini D, Rocchetti R, et al. Identification and characterization of cancer stem cells from head and neck squamous cell carcinoma cell lines. Cell Physiol Biochem. 2015;36(2):784-798.
Seta R, Mascitti M, Campagna R, et al. Overexpression of nicotinamide N-methyltransferase in HSC-2 OSCC cell line: effect on apoptosis and cell proliferation. Clin Oral Investig. 2019;23(2):829-838.